Company Encyclopedia
View More
name
WBDE
002082.SZ
Wanbangde Pharmaceutical Holding Group Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine, chemical raw materials, and chemical preparations in China and internationally. The company operates through Pharmaceutical Production and Sales, and Medical Equipment and Personal Equipment Production and Sale segments. It offers drugs products used to treat cardiovascular and cerebrovascular diseases; and nervous, respiratory, mental, and digestive system diseases.
3.157 T
002082.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking121/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE0.53%D
    • Profit Margin1.02%C
    • Gross Margin32.39%C
  • Growth ScoreD
    • Revenue YoY-13.26%E
    • Net Profit YoY-86.06%E
    • Total Assets YoY6.41%B
    • Net Assets YoY0.11%C
  • Cash ScoreC
    • Cash Flow Margin9762.76%A
    • OCF YoY-13.26%E
  • Operating ScoreD
    • Turnover0.31D
  • Debt ScoreB
    • Gearing Ratio39.09%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    WBDE: Subsidiary's product has received orphan drug designation in the United States

    On October 27th, WBDE announced that its wholly-owned subsidiary, WBDE Pharmaceutical Group Co., Ltd., recently received a recognition letter from the U.S. Food and Drug Administration (FDA), granting orphan drug designation for WP203A for the treatment of pemphigus. Pemphigus is a severe autoimmune blistering disease characterized by widespread loose blisters and erosions on the skin and mucous membranes

    Zhitong·
    SZ
    002082
    -1.51%
    Zhitong·
    SZ
    002082
    -1.51%

    The traditional Chinese medicine concept continues to rise, WBDE hits the limit up, Honz, TMSP, Zhenbao Island, JI LIN AO DONG and others follow suit

    Zhitong·
    SZ
    002082
    -1.51%
    SZ
    300086
    +0.82%
    SH
    600671
    +1.89%
    Zhitong·
    SZ
    002082
    -1.51%
    SZ
    300086
    +0.82%
    SH
    600671
    +1.89%

    Innovative drug concept experiences a surge, CCHT rises over 8%

    The innovative drug concept has seen a surge, with CCHT rising over 8%, Xinghao Pharmaceutical and WBDE rising over 5%, and Tibet Pharmaceutical, REMEGEN, Salubris, Cosunter, and INNOCARE also following suit

    Zhitong·
    SH
    688331
    +1.13%
    HK
    09995
    -1.51%
    SZ
    300436
    +0.09%
    Zhitong·
    SH
    688331
    +1.13%
    HK
    09995
    -1.51%
    SZ
    300436
    +0.09%

    WBDE: The share transfer price is adjusted to 8.61 yuan/share

    WBDE announced that its controlling shareholder, WBDE Group, and its concerted parties have adjusted the share transfer price from RMB 6.88 per share to RMB 8.61 per share. The transferee, Wanlong Pharmaceutical, needs to pay a total price of RMB 517 million. Payment will be completed within one month after the share transfer registration, and the share transfer is subject to review by the Shenzhen Stock Exchange

    Zhitong·
    SZ
    002082
    -1.51%
    Zhitong·
    SZ
    002082
    -1.51%

    WBDE: The first subject has been enrolled in the Phase II/III clinical trial of Shishanjianjia controlled-release tablets

    WBDE announced that the Phase II/III clinical trial of its wholly-owned subsidiary WBDE Pharmaceutical Group Co., Ltd.'s donepezil controlled-release tablets for the treatment of mild to moderate Alzheimer's disease has completed the enrollment of the first subject. The drug utilizes a biphasic controlled-release technology aimed at improving the onset speed and safety of the medication, and supports once-daily dosing to enhance patient convenience and compliance. This trial will validate its clinical value and provide new options for Alzheimer's disease treatment

    Zhitong·
    SZ
    002082
    -1.51%
    Zhitong·
    SZ
    002082
    -1.51%
    © 2025 Longbridge｜Disclaimer